Hanshang Group announced that the company will hold a 2026 semi-annual results briefing on September 1, 2026. In the first half of 2026, the company achieved operating income of 461 million yuan; net profit attributable to shareholders of listed companies was 4.1054 million yuan, an increase of 153.19% over the previous year, turning a loss into a profit. The company promoted the “big health, big business” dual business strategy. During the reporting period, it completed the acquisition of 75% of the shares of Ningbo Bairui Biotechnology Co., Ltd. through its wholly-owned subsidiary Dikang Pharmaceutical. Bai Rui Biotech has obtained 5 Class III medical device registration certificates. As of June 30, 2026, the total number of common shareholders of the company was 15,873. There is no mid-term dividend plan for the half-year period, and cancellation of early share repurchases has been initiated.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.